Cabotegravir's PrEP program reduces HIV incidence by 66% compared to Truvada

ViiV Healthcare recently reported the final data analysis of the IIb/III HPTN 083 study, which showed that pre-exposureprevention(PrEP) program, which includes the research-long cabotgravir, reduced HIV incidence by 66% compared to The Truvada (Nquatabin/Tenofovirest) of Gilead Sciencesafter a mid-term review, the study's blind period was discontinued in May this yearThe study showed that long-acting cabotegravir was 69 percent higher in hiv prevention than TruvadaThe latest findings will be presented july 8 at the International AIDS Congress (AIDS 2020)Kimberly Smith, head of research and development at ViiV, which is owned by GlaxoSmithKline, said: "This progress has the potential to change the prevention of AIDS, with the frequency of long-acting cabotegravir being significantly reduced and the number of administrations expected to be made only six times a year."HPTN 083 study, co-funded by the National Institutes of Health, was conducted in Argentina, Brazil, Peru, the United States, South Africa, Thailand and VietnamParticipants received cabotegravir every 8 weeks or Truvada or ally every day for a maximum of three yearsThe main efficacy endpoint of the trial was the recorded hivevents